SCNXHIGH SIGNALRISK10-K

SCNX has added explicit going concern language stating that substantial doubt exists about the company's ability to continue operations due to capital needs.

The addition of going concern warnings represents a material deterioration in management's assessment of the company's financial viability. The disclosure that additional capital "may not be available when needed or on commercially acceptable terms" signals acute near-term funding pressures that could threaten operations or force dilutive equity raises.

Comparing 2026-03-30 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

The company showed mixed financial performance with revenue growing meaningfully to $3.8M while reducing R&D expenses modestly to $2.0M. The balance sheet reflects some deleveraging with current liabilities declining substantially to $2.7M and total liabilities falling to $14.1M, though total assets also contracted to $84.2M and stockholders' equity decreased to $70.1M. Despite the liability reduction, the financial position appears insufficient to alleviate management's going concern warnings about future capital availability.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-65.4%
$7.9M$2.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
-46.9%
$23K$12K

Capex reduced 46.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-45.5%
$25.8M$14.1M

Liabilities reduced 45.5% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
+30.7%
$2.9M$3.8M

Strong top-line growth of 30.7% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+25.5%
$6.3M$7.9M

Current assets grew 25.5% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
-19.7%
$104.9M$84.2M

Total assets contracted 19.7% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-12.5%
$2.2M$2.0M

R&D spending cut 12.5% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-11.3%
$79.1M$70.1M

Equity decreased 11.3% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-26
ADDED
There were 40,630,815 shares of the registrant s common stock outstanding on March 27, 2026.
Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates.
Some of the statements in this Annual Report constitute forward-looking statements because they relate to future events or our future performance or future financial condition.
These risks include, among others, the following: We operate a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate its current business and predict its future success and viability.
We need additional capital which may not be available when needed or on commercially acceptable terms, thereby casting substantial doubt on our ability to continue as a going concern.
+7 more — sign up free →
REMOVED
Employer Identification No.) 6308 Benjamin Rd , Suite 708 Tampa , Florida 33634 (Address of principal executive offices) (Zip code) (800) 261-0281 (Registrant s telephone number, including area code) TRxADE HEALTH, INC.
There were 12,515,019 shares of the registrant s common stock outstanding on March 26, 2025.
Securities and Exchange Commission (the SEC ) on January 27, 2025, and the related additional soliciting materials filed with the SEC on February 18, 2025 within 120 days after the end of the fiscal year to which this Annual Report relates.
Some of the statements in this Registration Statement constitute forward-looking statements because they relate to future events or our future performance or future financial condition.
We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →